Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haohai Biological Technology Co (FRA:5HB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shanghai Haohai Biological Technology Co Receivables Turnover Related Terms
Shanghai Haohai Biological Technology Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co Receivables Turnover Chart
Shanghai Haohai Biological Technology Co Annual Data
FRA:5HB vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co Receivables Turnover vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Receivables Turnover of 2.23 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shanghai Haohai Biological Technology Co and its competitors. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #361 out of 841 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Shanghai Haohai Biological Technology Co's Receivables Turnover too high?
Shanghai Haohai Biological Technology Co's current Receivables Turnover is 2.23. The Biotechnology industry median Receivables Turnover is 5.27. Shanghai Haohai Biological Technology Co's value of 2.23 is 57.7% below this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #361 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #361 out of 841 companies for Receivables Turnover. This puts Shanghai Haohai Biological Technology Co in the upper half of its industry. The industry median Receivables Turnover is 5.27. Shanghai Haohai Biological Technology Co's value of 2.23 is 57.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current Receivables Turnover of 2.23 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current Receivables Turnover is 2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.71, compared to a current price of €1.74 — trading 35.8% below its estimated fair value. The current Receivables Turnover is 2.23 and 57.7% below the Biotechnology industry median of 5.27. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Receivables Turnover is 2.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.74 is trading 35.8% below its estimated GF Value™ of €2.71.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
Receivables Turnover: 2.23
GF Value™: €2.71 vs. price of €1.74 (35.8% below fair value)
Industry Position: 57.7% below the Biotechnology median (#361 of 841)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Business Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
